AzTrials
AzTrials

Relapsed or Refractory Multiple MyelomaPhase 3SUCCESSOR-2NCT05552976

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

A Phase 3 study testing Mezigdomide, Carfilzomib and Dexamethasone in people with Relapsed or Refractory Multiple Myeloma, run by Bristol-Myers Squibb at 204 sites in 27 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Relapsed or Refractory Multiple Myeloma
What is being tested?
Mezigdomide, Carfilzomib and Dexamethasone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
606 participants
Where
204 sitesin 27 countries
Study dates
10 Jan 2023to 25 Jul 2029
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.
  • Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.
  • M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.
  • For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.
  • Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).
  • Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible).
  • Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.
  • Participant must have documented disease progression during or after their last antimyeloma regimen.

Who cannot join

  • Participant who has had prior treatment with mezigdomide or carfilzomib.
  • Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Trial locations and contacts

204 sites in 27 countries.

204 sites in 27 countries

United States33 sites

  • Local Institution - 0289

    Annapolis, Maryland, 21401

  • Local Institution - 0348

    Atlanta, Georgia, 30303

  • Local Institution - 0291

    Atlanta, Georgia, 30322

  • Saint Alphonsus Regional Medical Center

    Boise, Idaho, 83706

  • Local Institution - 0204

    Boston, Massachusetts, 02215

  • Local Institution - 0005

    Cerritos, California, 90703

  • Local Institution - 0349

    Chattanooga, Tennessee, 37404

  • Local Institution - 0322

    Cleveland, Ohio, 44106

  • Local Institution - 0172

    Columbus, Ohio, 43214

  • Local Institution - 0341

    Fort Myers, Florida, 33901

  • Local Institution - 0337

    Fort Worth, Texas, 76104

  • Local Institution - 0338

    Greer, South Carolina, 29650

  • Local Institution - 0328

    Houston, Texas, 77025

  • Local Institution - 0044

    Houston, Texas, 77030

  • Local Institution - 0190

    Irvine, California, 92618

  • Local Institution - 0222

    Little Silver, New Jersey, 07739

  • Local Institution - 0187

    Los Angeles, California, 90017

  • Local Institution - 0336

    Marshfield, Wisconsin, 54449

  • Local Institution - 0346

    Minneapolis, Minnesota, 55404

  • Local Institution - 0046

    Mobile, Alabama, 36604

  • Local Institution - 0243

    Morgantown, West Virginia, 26506

  • Local Institution - 0323

    Nashville, Tennessee, 37203

  • Local Institution - 0345

    Norfolk, Virginia, 23502

  • Local Institution - 0321

    Providence, Rhode Island, 02903

  • Local Institution - 0343

    Roanoke, Virginia, 24014

  • Local Institution - 0344

    Santa Rosa, California, 95403

  • Local Institution - 0342

    St. Petersburg, Florida, 33705

  • Local Institution - 0339

    Stockton, California, 95204

  • Local Institution - 0006

    Tacoma, Washington, 98405

  • Local Institution - 0195

    Temple, Texas, 76508

  • Local Institution - 0199

    The Bronx, New York, 10467

  • Local Institution - 0347

    Vancouver, Washington, 98684

  • Local Institution - 0340

    West Palm Beach, Florida, 33401

Other trials in United States

China27 sites

  • Local Institution - 0061

    Beijing, Beijing Municipality, 100020

  • Local Institution - 0057

    Beijing, Beijing Municipality, 100043

  • Local Institution - 0056

    Beijing, Beijing Municipality, 100730

  • Local Institution - 0052

    Changchun, Jilin, 130021

  • Local Institution - 0071

    Changsha, Hunan, 410013

  • Local Institution - 0103

    Changsha, Hunan, 410013

  • Local Institution - 0123

    Fuzhou, Fujian, 350000

  • Local Institution - 0138

    Guangzhou, Guangdong, 510000

  • Local Institution - 0050

    Hangzhou, Zhejiang, 310003

  • Local Institution - 0072

    Jinan, Shandong, 250012

  • Local Institution - 0058

    Kunming, Yunnan, 650101

  • Local Institution - 0095

    Nanchang, Jiangxi, 330006

  • Local Institution - 0180

    Nanjing, Jiangsu, 210009

  • Local Institution - 0111

    Nantong, Jiangsu, 226001

  • Local Institution - 0118

    Shanghai, Shanghai Municipality, 200025

  • Local Institution - 0317

    Shanghai, Shanghai Municipality, 200080

  • Local Institution - 0096

    Shenyang, Liaoning, 110001

  • Local Institution - 0176

    Shenyang, Liaoning, 110004

  • Local Institution - 0104

    Suzhou, Jiangsu, 215006

  • Local Institution - 0059

    Taiyuan, 030032

  • Local Institution - 0091

    Tianjin, Tianjin Municipality, 300060

  • Local Institution - 0115

    Wenzhou, Zhejiang, 32500

  • Local Institution - 0066

    Wuhan, Hubei, 430002

  • Local Institution - 0054

    Wuhan, Hubei, 430030

  • Local Institution - 0069

    Wuxi, Jiangsu, 214023

  • Local Institution - 0060

    Xi'an, Shaanxi, 710126

  • Local Institution - 0051

    Zhengzhou, Henan, 450008

Other trials in China

Japan22 sites

  • Local Institution - 0215

    Chiba, 260-8677

  • Local Institution - 0303

    Chūō, Yamanashi, 409-3898

  • Local Institution - 0226

    Fukuoka, 810-8563

  • Local Institution - 0235

    Fukuoka, 815-8555

  • Local Institution - 0217

    Higashiibaraki, Ibaraki, 3113117

  • Local Institution - 0234

    Kamakura, Kanagawa, 247-8533

  • Local Institution - 0300

    Kanazawa, Ishikawa-ken, 920-8641

  • Local Institution - 0214

    Kashiwa, Chiba, 277-8577

  • Local Institution - 0210

    Kitakyushu-shi, Fukuoka, 806-8501

  • Local Institution - 0225

    Koshigaya, Saitama, 343-0845

  • Local Institution - 0219

    Koto-ku, Tokyo, 135-8550

  • Local Institution - 0220

    Kumamoto, 860-8556

  • Local Institution - 0216

    Kyoto, 602-8566

  • Local Institution - 0213

    Nagasaki, 852-8104

  • Local Institution - 0269

    Nagoya, Aichi-ken, 467-8602

  • Local Institution - 0212

    Okayama, 701-1192

  • Local Institution - 0301

    Osaka, 545-8586

  • Local Institution - 0211

    Sapporo, Hokkaido, 003-0804

  • Local Institution - 0209

    Shiwa-gun Yahaba-cho, Iwate, 028-3695

  • Local Institution - 0236

    tabashi City, Tokyo, 173-8610

  • Local Institution - 0241

    Tokyo, 105-8461

  • Local Institution - 0218

    Tokyo, 150-8935

Other trials in Japan

Germany14 sites

  • Local Institution - 0007

    Berlin, 12203

  • Local Institution - 0102

    Cologne, 50937

  • Local Institution - 0335

    Dortmund, North Rhine-Westphalia, 44263

  • Local Institution - 0329

    Dresden, 01307

  • Local Institution - 0334

    Düsseldorf, 40479

  • Local Institution - 0333

    Hanover, Lower Saxony, 30161

  • Local Institution - 0015

    Heidelberg, D-69120

  • Local Institution - 0331

    Jena, Thuringia, 07747

  • Local Institution - 0029

    Kiel, Schleswig-Holstein, 24105

  • Local Institution - 0030

    Leipzig, 04103

  • Local Institution - 0330

    Munich, Bavaria, 81241

  • Local Institution - 0133

    Nuremberg, 90419

  • Local Institution - 0124

    Ulm, Baden-Wurttemberg, 89081

  • Local Institution - 0014

    Würzburg, 97080

Other trials in Germany

India11 sites

  • Local Institution - 0161

    Bengaluru, Karnataka, 560027

  • Local Institution - 0230

    Chandigarh, 160012

  • Local Institution - 0174

    Chennai, Tamil Nadu, 600036

  • Local Institution - 0167

    Gurgaon, Haryana, 122001

  • Local Institution - 0165

    Hyderabad, Telangana, 500033

  • Local Institution - 0310

    Hyderabad, Telangana, 500068

  • Local Institution - 0164

    Hyderabad, Telangana, 500084

  • Local Institution - 0261

    Mohali, Punjab, 160055

  • Local Institution - 0168

    Mumbai, Maharashtra, 400012

  • Local Institution - 0170

    New Delhi, National Capital Territory of Delhi, 110085

  • Local Institution - 0171

    Thane, Maharashtra, 400602

Other trials in India

Australia10 sites

  • Local Institution - 0024

    Adelaide, South Australia, 5000

  • Local Institution - 0131

    Bendigo, Victoria, 3550

  • Local Institution - 0077

    Camperdown, New South Wales, 2050

  • Local Institution - 0224

    East Melbourne, Victoria, 3002

  • Local Institution - 0160

    Gosford, New South Wales, 2250

  • Local Institution - 0127

    Heidelberg, Victoria, 3084

  • Local Institution - 0025

    Melbourne, Victoria, 3065

  • Local Institution - 0263

    Port Macquarie, New South Wales, 2444

  • Local Institution - 0078

    St Leonards, New South Wales, 2065

  • Local Institution - 0026

    Sydney, New South Wales, 2010

Other trials in Australia

Spain10 sites

  • Local Institution - 0126

    Badalona, Barcelona [Barcelona], 08916

  • Local Institution - 0092

    Barcelona, Barcelona [Barcelona], 08035

  • Local Institution - 0107

    Granada, 18012

  • Local Institution - 0038

    L'Hospitalet Del Llobregat, Barcelona [Barcelona], 08908

  • Local Institution - 0200

    Madrid, Madrid, Comunidad de, 28009

  • Local Institution - 0047

    Madrid, 28015

  • Local Institution - 0108

    Majadahonda, Madrid, Comunidad de, 28222

  • Local Institution - 0105

    Málaga, 29010

  • Local Institution - 0201

    San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320

  • Local Institution - 0037

    Valencia, Valenciana, Comunitat, 46010

Other trials in Spain

Italy8 sites

  • Local Institution - 0189

    Bologna, 40138

  • Local Institution - 0148

    Catanzaro, 88100

  • Local Institution - 0147

    Lecce, 73100

  • Local Institution - 0145

    Meldola, Emilia-Romagna, 47014

  • Local Institution - 0143

    Milan, Lombardy, 20122

  • Local Institution - 0144

    Pisa, 56100

  • Local Institution - 0142

    Rozzano, Milano, 20089

  • Local Institution - 0146

    Udine, 33100

Other trials in Italy

Argentina6 sites

  • Local Institution - 0079

    ABB, Buenos Aires F.D., C1199ABB

  • Local Institution - 0150

    Buenos Aires, 1431

  • Local Institution - 0008

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ

  • Local Institution - 0151

    Córdoba, 5000

  • Local Institution - 0182

    Rosario, Santa Fe Province, 2000

  • Local Institution - 0319

    San Miguel de Tucumán, Tucumán Province, 4000

Other trials in Argentina

Taiwan6 sites

  • Local Institution - 0274

    Chiayi City, Chiayi, 613

  • Local Institution - 0012

    Kaohsiung City, 82445

  • Local Institution - 0177

    Kaohsiung Niao Sung Dist, Kaohsiung, 83301

  • Local Institution - 0001

    Taichung, 407

  • Local Institution - 0002

    Tainan, 704

  • Local Institution - 0162

    Taipei, 11217

Other trials in Taiwan

United Kingdom6 sites

  • Local Institution - 0273

    Birmingham, B9 5SS

  • Local Institution - 0067

    Cringleford, England, NR4 7UY

  • Local Institution - 0196

    Glasgow, Glasgow City, G12 0YN

  • Local Institution - 0080

    Leeds, LS9 7TF

  • Local Institution - 0139

    Plymouth, Devon, Pl6 8DH

  • Local Institution - 0040

    Taunton, TA1 5DA

Other trials in United Kingdom

Brazil5 sites

  • Local Institution - 0076

    Porto Alegre, Rio Grande do Sul, 90470-340

  • Local Institution - 0075

    Rio de Janeiro, 20775-001

  • Local Institution - 0121

    Salvador, Estado de Bahia, 41253-190

  • Local Institution - 0085

    São Paulo, São Paulo, 01509-010

  • Local Institution - 0073

    São Paulo, 04537-080

Other trials in Brazil

Colombia5 sites

  • Local Institution - 0154

    Bogota, Cundinamarca, 111151

  • Local Institution - 0155

    Cali, 760035

  • Local Institution - 0153

    Medellín, Antioquia, 05034

  • Local Institution - 0324

    Piedecuesta, Santander Department, 681017

  • Local Institution - 0156

    Valledupar, Cesar Department, 200001

Other trials in Colombia

Hungary5 sites

  • Local Institution - 0042

    Budapest, 1088

  • Local Institution - 0019

    Budapest, 1097

  • Local Institution - 0043

    Debrecen, Hajdú-Bihar, 4032

  • Local Institution - 0094

    Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400

  • Local Institution - 0036

    Pécs, Baranya, 7624

Other trials in Hungary

Romania5 sites

  • Local Institution - 0284

    Brasov, 500052

  • Local Institution - 0282

    Bucharest, Bucharest, 022328

  • Local Institution - 0302

    Bucharest, 022328

  • Local Institution - 0287

    Bucharest, 030171

  • Local Institution - 0306

    Sibiu, 557260

Other trials in Romania

Denmark4 sites

  • Local Institution - 0032

    Aarhus, Central Jutland, 8200

  • Local Institution - 0129

    Odense, Region Syddanmark, 5000

  • Local Institution - 0065

    Roskilde, Region Sjælland, 4000

  • Local Institution - 0125

    Vejle, 7100

Other trials in Denmark

Austria3 sites

  • Local Institution - 0020

    Linz, 4020

  • Local Institution - 0266

    Vienna, State of Vienna, 1060

  • Local Institution - 0017

    Vienna, 1090

Other trials in Austria

Bulgaria3 sites

  • Local Institution - 0305

    Plovdiv, 4002

  • Local Institution - 0309

    Sofia, 1407

  • Local Institution - 0304

    Sofia, 1431

Other trials in Bulgaria

Canada3 sites

  • Local Institution - 0183

    Halifax, Nova Scotia, B3H 2Y9

  • Local Institution - 0275

    London, Ontario, N6A 5W9

  • Local Institution - 0184

    Toronto, Ontario, M5G 2M9

Other trials in Canada

Greece3 sites

  • Local Institution - 0135

    Athens, Attikí, 11528

  • Local Institution - 0136

    Pátrai, Achaḯa, 26504

  • Local Institution - 0134

    Thessaloniki, Thessaloníki, 570 10

Other trials in Greece

Israel3 sites

  • Local Institution - 0264

    Holon, Central District, 5810001

  • Local Institution - 0277

    Jerusalem, 9112001

  • Local Institution - 0267

    Tsrifin, Central District, 70300

Other trials in Israel

Norway3 sites

  • Local Institution - 0049

    Bergen, Hordaland, 5021

  • Local Institution - 0081

    Oslo, 0450

  • Local Institution - 0112

    Stavanger, Rogaland, 4021

Other trials in Norway

South Korea3 sites

  • Local Institution - 0238

    Seoul, Seoul-teukbyeolsi [Seoul], 03080

  • Local Institution - 0239

    Seoul, Seoul-teukbyeolsi [Seoul], 06351

  • Local Institution - 0240

    Seoul, Seoul-teukbyeolsi [Seoul], 06591

Other trials in South Korea

Netherlands2 sites

  • Local Institution - 0113

    Breda, North Brabant, 4818 CK

  • Local Institution - 0194

    Enschede, 7512 KZ

Other trials in Netherlands

Singapore2 sites

  • Local Institution - 0158

    Singapore, Central Singapore, 119074

  • Local Institution - 0159

    Singapore, Central Singapore, 169608

Other trials in Singapore

Hong Kong1 site

  • Local Institution - 0178

    Hksar, 0

Other trials in Hong Kong

Puerto Rico1 site

  • Local Institution - 0316

    San Juan, 00909

Other trials in Puerto Rico

About this study

Official title: A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

Being tested
Mezigdomide, Carfilzomib, Dexamethasone
Keywords
BMS-986348, CC-92480, Carfilzomib, Dexamethasone, Multiple Myeloma, Mezigdomide
Medical subject headings
Recurrence, Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MezigdomideDrug

    Also called BMS-986348, CC-92480

    Specified dose on specified days

  • CarfilzomibDrug

    Also called Kyprolis

    Specified dose on specified days

  • DexamethasoneDrug

    Also called Decadron, Dex

    Specified dose on specified days

Study groups in NCT05552976
Study groupRoleWhat they receive
MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)ExperimentalNot described
Receives: Drug: Mezigdomide; Drug: Carfilzomib; Drug: Dexamethasone
Kd (Carfilzomib + Dexamethasone)Active comparatorNot described
Receives: Drug: Carfilzomib; Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-free Survival (PFS)

    Measured: Up to approximately 5 years

Secondary outcomes (15)

  1. Recommended Mezigdomide Dose

    Stage 1 only

    Measured: Up to 12 months

  2. Plasma concentrations of Mezigdomide in Combination with Carfilzomib and Dexamethasone

    Stage 1 only

    Measured: Up to 176 days

  3. Overall Survival (OS)

    Measured: Up to approximately 5 years

  4. Overall Response (OR)

    Measured: Up to approximately 5 years

  5. Rate Of Very Good Partial Response (VGPR) Or Better (VGPRR)

    VGPRR will be calculated as the percentage of participants who achieve best response of VGPR or better according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma.

    Measured: Up to approximately 5 years

  6. Complete Response (CR) Or Better (CRR)

    CRR will be calculated as the percentage of participants who achieve best response of CR or better according to the IMWG Uniform Response Criteria for Multiple Myeloma.

    Measured: Up to approximately 5 years

  7. Time To Response (TTR)

    Measured: Up to approximately 5 years

  8. Duration Of Response (DOR)

    Measured: Up to approximately 5 years

  9. Time To Progression (TTP)

    Measured: Up to approximately 5 years

  10. Time To Next Treatment (TTNT)

    Measured: Up to approximately 5 years

  11. Progression-free Survival 2 (PFS-2)

    Measured: Up to approximately 5 years

  12. Minimal Residual Disease (MRD) Negativity Rate

    Measured: Up to approximately 5 years

  13. Number Of Participants With Adverse Events (AEs)

    Measured: Up to approximately 5 years

  14. Change From Baseline in the European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)

    The EORTC QLQ-C30 is the most commonly used quality of life instrument in oncology trials. The QLQ-C30 consists of 30 questions incorporated into 5 functional domains physical, role, cognitive, emotional, and social), 9 symptom/other scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global Quality of Life (QoL)/global health status score. Items in the functional and symptom scale use raw participant response of 1 to 4, where 1 = "not at all" and 4 = "very much." The 2 global items contain responses ranging from 1 "very poor" to 7 "excellent." The recall period is 1 week. All domain scores are transformed in a range from 0 to 100, where a higher functional score indicates more favorable outcomes and a higher score on the symptom domains indicates a less favorable participant outcome. Stage 2 only.

    Measured: Up to approximately 5 years

  15. Change From Baseline in the European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)

    The EORTC QLQ-MY20 is a 20-item myeloma module intended for use among participants varying in disease stage and treatment modality. Participants rate symptoms or problems on a scale from 1 to 4 where 1 = "not at all" and 4 = "very much." Stage 2 only.

    Measured: Up to approximately 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Sep 2022
  2. Study start10 Jan 2023
  3. Primary completion28 Sep 2026 (estimated)
  4. Study completion25 Jul 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a two-stage inferentially seamless design.
Masking
None (open label)
Enrolment
606 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05552976
Sponsor's protocol ID
CA057-008
Acronym
SUCCESSOR-2
Status last verified
Sep 2026
First submitted
21 Sep 2022
Last updated
24 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Publications

  • Dimopoulos MA, Schjesvold F, Fu C, Hartley-Brown MA, Gomez C, Reece D, Mikala G, Alkharabsheh O, Parrish C, de Queiroz Crusoe E, Galvez K, Idrobo H, White D, Gupta R, Lee C, Liu CJ, Quach H, Wang Y, Cerchione C, Forsyth C, Hungria V, Kalaskar P, Graklanov V, Ho PJ, Klaiber-Hakimi M, Kwong YL, Louzada M, Mazumder A, Miles O, Nagarajan C, Prasad SVSS, Raab MS, Varga G, von der Heyde E, Xia Z, Ochoa PA, Oriol A, Yuda J, Kuroda J, Gong J, Zhou Z, Maciag P, Yu B, Rocci A, Koo P, Katz J, Richardson PG; SUCCESSOR-2 Trial Investigators. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Lancet. 2026 Jul 18;408(10551):219-233. doi: 10.1016/S0140-6736(26)01088-3. Epub 2026 Jun 14.

    PubMed 42289183

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Mezigdomide, Carfilzomib and Dexamethasone in people with Relapsed or Refractory Multiple Myeloma, run by Bristol-Myers Squibb at 204 sites in 27 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 204 sites in United States, China, Japan, Germany, India and 22 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-free Survival (PFS) (time frame: Up to approximately 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05552976, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in